Onconova Therapeutics Inc Share Price Nasdaq
Equities
US68232V3069
Biotechnology & Medical Research
Sales 2024 * | 210K 17.53M | Sales 2025 * | 300K 25.04M | Capitalization | 10.12M 845M |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.92B | Net income 2025 * | -28M -2.34B | EV / Sales 2024 * | 48.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 33.7 x |
P/E ratio 2024 * |
-0.46
x | P/E ratio 2025 * |
-0.48
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.37% |
Latest transcript on Onconova Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Guerin
DFI | Director of Finance/CFO | 55 | 01/13/01 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 24/23/24 |
Victor Moyo
CTO | Chief Tech/Sci/R&D Officer | - | 24/23/24 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 01/15/01 |
Jack Stover
BRD | Director/Board Member | 69 | 23/16/23 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 01/20/01 |
1st Jan change | Capi. | |
---|---|---|
+18.30% | 44.44B | |
+41.98% | 40.03B | |
-10.33% | 37.68B | |
+31.53% | 31.46B | |
-7.79% | 27.29B | |
+13.64% | 26.29B | |
+42.33% | 13.8B | |
+30.58% | 12.46B | |
-7.56% | 11.26B |